Inhibitor Therapeutics, Inc.
INTI· OTC
INTIInhibitor Therapeutics, Inc.
Filed May 15, 2026 · 10-Q · 45 days after period end · 0001493152-26-023622
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$686.43K | -$632.85K | -$684.71K | -$539.60K |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 15, 2026 · 45 d after period end
